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Highlights 
• 
We characterized AP-1 expression in normal and preeclamptic PDMSCs. 
• 
JunB was significantly increased in PE vs control PDMSCs. 
• 
Cyclin-D1 was significantly down-regulated in PE vs control PDMSCs. 
• 
JunB siRNA was accompanied by increased Cyclin-D1 in normal PDMSCs. 
• 
We demonstrated that JunB over-expression in PE-PDMSCs affects Cyclin-D1 regulation. 
 Abstract 
Introduction 
In the present study, we characterized the expression of Activating Protein 1 (AP-1) factors, key 
cell cycle regulators, in primary placental mesenchymal stromal cells (PDMSCs) derived from 
normal and preeclamptic (PE) pregnancies with fetal-placental compromise. 
Methods 
PDMSCs were isolated from control (n = 20) and preeclamptic (n = 24) placentae. AP-1 expression 
was determined by semi-quantitative RT-PCR (sqRT-PCR), Real Time PCR and Western Blot 
assay. PDMSCs were plated and JunB siRNA was performed. JunB and Cyclin-D1 expression were 
assessed by Real Time and Western Blot analyses. 
Results 
JunB expression was significantly increased while Cyclin-D1 expression was significantly down-
regulated in PE relative to control PDMSCs. JunB siRNA was accompanied by JunB down-
regulation and increased Cyclin-D1 in normal PDMSCs. 
Conclusions 
We described, for the first time, AP-1 expression in PDMSCs derived from physiological and PE 
placentae. Importantly, we demonstrated that JunB over-expression in PE-PDMSCs affects Cyclin-
D1 regulation. Our data suggest a possible contribution of these pathological placental cells to the 
altered cell cycle regulation typical of preeclamptic placentae. 
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1. Introduction 
Preeclampsia (PE) is a severe pregnancy-related syndrome affecting about 5–8% of all women 
worldwide, and is thus a leading cause of fetal–maternal mortality and morbidity [1] Preeclamptic 
pregnancies are characterized by abnormal placenta development with immature hyper-proliferative 
trophoblast phenotype and shallow invasion of maternal spiral arteries [2], [3] and [4]. These 
defects entail placental hypoperfusion that, in the most severe cases, it is associated to fetal growth 
restriction (FGR) [5] and [6]. 
During the last years, the investigation of the complex PE pathogenesis has been mainly focused on 
the trophoblast, considered the main site of those placental aberrations responsible for PE onset. 
Nevertheless, we recently demonstrated the central role of placental derived mesenchymal stromal 
cells (PDMSC) in placental physiopathology. We reported aberrant release of pro-inflammatory 
cytokines by PDMSCs derived from preeclamptic placental villi (PE-PDMSCS) and their ability to 
induce a PE-like phenotype in term physiological villous explants [7]. Moreover, mesenchymal 
stromal cells are the most abundant placental cellular component and they represent the structural 
support for the forming primary villi during placental development, and they may drive capillary 
network establishment [8] and [9]. We described a slow PE-PDMSCs proliferation rate 
accompanied by increased senescence [7], thus indicating the contribution of PE-PDMSCs to the 
aberrant villous architecture typical of PE. Indeed, PDMSCs could directly cause or contribute to 
the placental anomalies typical of PE and FGR. 
Activating Protein-1 (AP-1) early response proto-oncogenes are key cell cycle modulators pivotal 
for appropriate placentation. The inducible AP-1 transcription factors are dimeric complexes that 
contains members of the Jun and Fos protein families. While Fos proteins (c-Fos, FosB, Fra1, Fra2) 
hetero-dimerize only with members of the Jun family, Jun proteins (c-Jun, JunB, JunD) both homo- 
and heterodimerize with Fos members to form transcriptionally active complexes. Our group 
recently demonstrated an aberrant AP-1 expression pattern in the PE trophoblast [10]. 
In the present study, we investigated the expression of AP-1 family members in PDMSCs derived 
from normal and PE placentae with fetal-placental compromise in order to determine whether AP-1 
dysregulation could also be present in pathological placental mesenchymal cells as we previously 
demonstrated for trophoblast [10]. 
2. Materials and methods 
2.1. Ethics statement 
The study was approved by the Institutional Ethical Committee of O.I.R.M. S.Anna Hospital and 
“Ordine Mauriziano di Torino” (n.209; protocol 39226/C.27.1 04/08/09) (Turin, Italy). All patients 
provided written informed consent for samples collection and subsequent analysis. 
2.2. Patients 
The study population included 24 singleton pregnancies complicated by severe preeclampsia fetal-
placental compromise and 20 physiological term control pregnancies (Table 1). PE diagnosis was 
made according to the following criteria [1]: hypertension (systolic blood pressure ≥140 mmHg or 
diastolic blood pressure ≥90 mmHg) and proteinuria (>300 mg/24 h) after twenty week of 
gestational age in previously normotensive women. FGR was defined as birth weight below the 
fifth centile according to the Italian growth curves normalized for gestational age and sex 
[11] and [12] accompanied by pathological umbilical artery Doppler waveforms (absent or reverse 
end diastolic flow – A/REDF) and increased resistance to flow in maternal uterine arteries (early 
diastolic notch or pulsatility index – PI – more than 0.58). Control patients were healthy women 
with singleton term physiological normotensive pregnancies and no signs of preeclampsia or FGR. 
Exclusion criteria were: congenital malformation, chromosomal abnormalities (in number and/or 
structure), maternal and/or intrauterine infections, cardiovascular diseases and metabolic syndrome. 
Table 1.  
Clinical features of the study population. 
 
Controls (n = 20) Preeclampsia (n = 24) P value 
Nulliparae (%) 30 41.6 n.s. 
Gestational age at delivery (weeks) 
39.5 ± 1.08 (37–
41) 
33.6 ± 3.30 (28–41) p < 0.01 
Maternal age at delivery (years) 
33.1 ± 4.54 (24–
41) 
33.4 ± 5.63 (20–41) n.s 
Ethnicity (%) 
 Caucasian 100 100 
 
Prenatal medications (%) 
 Albumin – 12.5 
 
 Antibiotics 15 16.6 
 
 Antidepressant – 4.1 
 
 Diuretics – 12.5 
 
 Eutirox 5 – 
 
 Folin 10 4.1 
 
 Heparin – 4.1 
 
 Iron 5 4.1 
 
 Proton Pump Inhibitors (PPIs) 5 16.6 
 
 Ventolin 5 4.1 
 
Smokers (%) 10 – 
 
Alcohol (%) 15 – 
 
Previous prenatal admission (%) 10 33.3 
 
Systolic Blood pressure (mm Hg) 114.7 ± 14.18 150 ± 19.41 <0.01 
Diastolic Blood pressure (mm Hg) 73 ± 10 95 ± 12.18 <0.01 
Proteinuria (g/24 h) Absent 2.92 ± 4.57 <0.01 
A/REDF (%) 0 58.3 <0.01 
Pathological Uterine Doppler (%) 0 75 <0.01 
Labor (%) 60 25 p = 0.03 
 Antibiotics in labor (%) 25 100 <0.01 
Delivery to processing (range in 
hours) 
0–3 0–3 
 
Caesarean section (%) 55 87.5 p = 0.02 
Anesthesia (%) 80 91.6 n.s. 
 Local 37.5 – 
p = 0.01 
 Spinal 62.5 86.36 
 
Controls (n = 20) Preeclampsia (n = 24) P value 
 Epidural – 9.1 
 General – 4.54 
Maternal oxygen given at delivery? 
(%) 
– 25 n.s. 
Birth weight (g) 3530.5 ± 379.54 
AGA 
(n = 8):2490 ± 845.3 
FGR 
(n = 16):1245 ± 473.9 
p = 0.017 
<0.01 
Placental weight (g) 598 ± 95.27 349.9 ± 123.1 <0.01 
Fetal sex (%) 
  
n.s. 
 Male 65 45.8 
  Female 35 54.2 
Magnesium sulfate (%) – 50 <0.01 
Values are expressed as mean ± SD and percentage. *p < 0.05. A.G.A, appropriate for 
gestational age; FGR, fetal growth restriction; n.s. not significant. 
Table options 
2.3. Placenta-derived mesenchymal stromal cells (PDMSCs) isolation and 
characterization 
PDMSCs were isolated by enzymatic digestion and gradient as previously described [7]. Briefly, 
the decidua was peeled off from the basal plate and removed in order to avoid maternal cell 
contamination. Next, membranes were removed and 30 g of villous tissue were sampled from the 
chorionic plate. Placental tissue was washed several times with Hank's Buffered Salt Solution 
(HBSS, Gibco, Life Technologies, Italy) in order to remove the excess of blood and next it was 
mechanically minced and digested for 3 h with 100 U/ml collagenase type I (Gibco, Life 
Technologies, Italy) plus 5 μg/ml DNAse I (Gibco, Life Technologies, Italy). Finally, cells were 
separated by gradient using 1.073 Ficoll Paque Premium (GE Healthcare Europe, Italy). The 
mononuclear cells ring was collected, washed and PDMSCs were resuspended in Dulbecco's 
modified Minimum Essential Medium (DMEM, Gibo, Life Technologies, Italy) supplemented with 
10% Fetal Bovine Serum (FBS Australian origin, Italy) and maintained at 37 °C and 5% CO2. After 
passage five, physiological and PE PDMSCs were characterized by flow cytometry for the 
expression of the following antigens: HLA-I, HLA-DR, CD105, C166, CD90, CD34, CD73, 
CD133, CD20, CD326, CD31, CD45 and CD14 (Miltenyi Biotech, Italy). Normal and PE-PDMSCs 
were analyzed by semi-quantitative PCR to assess gene expression levels of stem cell markers Oct-
4 and Nanog. Primers were designed as previously described [7]. Moreover, at the same passage, 
control and PE-PDMSCs were plated in 6 well plates at a density of 1 × 10
5
 cells/ml in DMEM LG 
without FBS. After 72 h of culture, cells were collected and processed for mRNA and protein 
isolation. 
2.4. RNA isolation and Real Time PCR 
Total RNA was isolated from physiological and PE-PDMSCs using TRIzol reagent (Life 
Technologies, Italy) according to manufacturer's instructions. Genomic DNA contamination was 
removed by DNAse I digestion before RT-PCR. cDNA was generated from 5 μg of total RNA 
using a random hexamers approach and RevertAid H Minus First Strand cDNA Synthesis kit 
(Fermentas, Italy). 
mRNA expression levels of JunB, JunD, c-Jun, FosB, c-Fos, Fra-1 and Fra-2 were first assessed by 
sqRT-PCR in order to identify possible splicing variants. Human 18S rRNA was used as 
housekeeping gene to normalize the data. Primers sequences, annealing temperatures and expected 
amplicon size were designed as previously published [10]. 
Gene expressions levels of JunB, Cyclin D1 and sex determining region gene of the Y chromosome 
(SRY) were determined by Real Time PCR using specific TaqMan primers and probes (Life 
Technologies, Italy) following the manufacturer's TaqMan protocol. Gene expression levels were 
normalized using endogenous 18s as internal reference (Life Technologies, Italy). Relative 
expression and fold change were calculated according to Livak and Schmittgen [13]. 
2.5. Western blot analyses 
Total proteins were isolated from PDMSCs using 1× Radio Immuno-precipitation Assay (RIPA) 
buffer. Thirty μg of total protein from PDMSCs were processed by SDS-page on 4–20% and 7.5% 
polyacrylamide pre-cast gradient gels (Bio-Rad Laboratories S.r.l., Italy). Next, proteins were 
transferred on PVDF membranes and probed at room temperature with primary antibodies using the 
SnapID system (Merck-Millipore, Italy) following the manufacturer's instructions. Primary 
antibodies were: rabbit polyclonal anti-human JunB (07-1333, 1:2000 dilution, Merk-Millipore, 
Italy), rabbit polyclonal anti-human Fra-1 (sc-183, 1:500 dilution, Santa Cruz Biotechnology, 
USA), rabbit polyclonal anti-human Fra-2 (sc-604, 1:500 dilution, Santa Cruz Biotechnology, 
USA), mouse monoclonal anti-human Cyclin D1 (2926s, 1:1500 dilution, Cell Signalling, USA), 
Biotinylated secondary antibodies were goat anti-mouse for Cyclin D1, (1:1000 dilution, Vector 
Laboratories, UK), donkey anti-rabbit for JunB, Fra-1, Fra-2 (1:1000 dilution, Vector Laboratories, 
UK). Protein expression levels were normalized to β-actin by blotting with mouse monoclonal anti-
human β-actin antibody (1:1000, Sigma–Aldrich, Italy) after stripping with 10× ReBlot Plus Strong 
Antibody Stripping Solution (Merck Millipore, Italy). Protein expression levels were assessed by 
chemo-luminescence using LuminataTM Classico Western HRP reagent (Merck Millipore, Italy) 
followed by densitometry. 
2.6. Immunoprecipitation 
Fra-1, Fra-2 and JunB association levels in normal and PE-PDMSCs were determined by 
immunoprecipitation. Briefly, one hundred μg of cell lysates were incubated with rabbit polyclonal 
anti-human Fra-1 (1:1000 dilution, Santa Cruz Biotechnology, USA) or rabbit polyclonal anti-
human Fra-2 antibodies (1:1000 dilution, Santa Cruz Biotechnology, USA) for 2 h at 4 °C on a 
rotator and next incubated with protein A-Sepharose beads (SantaCruz Biotechnology, USA) at 
4 °C overnight. Next, immunocomplexes were precipitated by centrifugation, separated from 
protein A-sepharose beads and denaturated by heating at 95 °C for 5 min. Finally, 
immunocomplexes were subjected to SDS-PAGE and blotted with anti-JunB antibody as described 
above. 
2.7. JunB silencing in placenta derived mesenchymal stromal cells 
Control PDMSC were plated at a density of 3 × 10
4
 cells/well in 24 well plates and cultured in 
DMEM LG without antibiotics at standard culture conditions (5% CO2, 37 °C). When cells reached 
70% confluency, they were transfected with 400 nM of StealthTM RNAi directed against human 
JunB gene (Invitrogen, Life Technologies, Italy) using LipofectamineTM 2000 (Invitrogen, Life 
Technologies, Italy) following manufacturer's protocol. PDMSCs transfected with 400 nM 
StealthTM RNAi Negative Control (scrambled sequences – SS) (Invitrogen, Life Technologies, 
Italy) were used as a control. Cells were processed for mRNA and protein isolation. 
2.8. Statistical analysis 
All data are represented as mean ± SE. For comparison of data between multiple groups we used 
one-way analysis of variance (ANOVA) with posthoc Dunnett's test. For comparison between 2 
groups we used paired and unpaired Student's t-test as appropriate. Categorical variables are 
presented as frequencies (percentages) and the comparison among different groups was done with 
χ2 by means of a 2 × 2 or 2 × 3 contingency table; Fisher's exact test was used for small sample 
sizes. Statistical test were carried out using SPSS Version 18 statistical software and significance 
was accepted at P < 0.05. 
3. Results 
3.1. Study population 
The clinical features of the study population were reported in Table 1. Control (n = 20) and PE 
(n = 24) pregnancies were comparable for maternal age, while gestational age (p < 0.01, 1.17 Fold 
Decrease), neonatal weight (CTRL vs PE-AGA p = 0.01, 1.41 Fold Decrease, CTRL vs PE-FGR 
p < 0.01, 2.83 Fold Decrease) and placental weight (p < 0.01, 1.7 Fold Decrease) at delivery were, 
as expected, significantly lower in PE group vs controls. All PE pregnancies presented fetal-
placental compromise with abnormal umbilical artery (58.3%, p < 0.01) and/or uterine artery (75%, 
p < 0.01) abnormal Doppler velocimetries associated in 66.6% of the cases with FGR (p < 0.01). 
3.2. Characterization of placenta-derived MSCs 
All PDMSCs cell lines (n = 44) displayed the proper mesenchymal stromal phenotype as assessed 
by flow cytometry. Cells were positive for CD105, CD166, CD90, CD73 and negative for HLA-II, 
for hematopoietic surface markers CD34 and CD45 and endothelial progenitor markers CD133 and 
CD31 ( Supplementary Fig. 1Sa). Control and PE PDMSCs were also negative for B cell, 
neutrophil and macrophage markers CD20 and CD14 and for trophoblast and epithelial markers 
CD326 (Supplementary Fig. 1Sa), thus excluding any significant contamination. RT-PCR detected 
the expression of typical stemness markers Oct-4 and Nanog, in all PDMSCs cell lines (n = 44) ( 
Supplementary Fig. 1Sb). Finally, to characterize control and PE PDMSCs genotype and to confirm 
absence of maternal cells contamination, PDMSCs isolated from placentae of male fetuses were 
tested for SRY expression by Real Time PCR. All our PDMSCs lines derived from placentae of 
male fetus (n = 24) resulted positive for SRY mRNA expression indicating the absence of 
significant maternal cell contamination that, if present, would have become prevalent ( 
Supplementary Fig. 1Sc). 
3.3. AP-1 family members expression in physiological and PE-PDMSCs 
We previously demonstrated aberrant expression of AP-1 factors in preeclamptic placental tissue 
relative to controls [10]. Therefore, we first investigated the expression of AP-1 family members in 
MSCs derived from both physiological (n = 20) and preeclamptic (n = 24) placentae by semi-
quantitative RT-PCR in order to identify possible splicing variants. We showed that all AP-1 
members were expressed in PDMSCs except for FosB, not present in both control and PE cells ( 
Fig. 1a). Moreover, PE-PDMSCs expressed significantly higher JunB mRNA levels relative to 
controls (p < 0.01, 1.66 Fold Increase) ( Fig. 1a). JunB gene expression levels were confirmed by 
quantitative Real Time PCR showing significantly increased mRNA expression levels in PE-
PDMSCs relative to controls (p = 0.02, 1.86 Fold Increase) ( Fig. 1b left panel). Western Blot 
analyses showed increased JunB protein expression levels in PE-PDMSCs compared to control 
cells (p < 0.01, 2.00 Fold-Increase), confirming data obtained at the mRNA level ( Fig. 1b right 
panel). Finally, to rule out the possibility that JunB expression could be a cell culturing artefact, we 
tested its expression in freshly isolated, unpassaged, normal and PE PDMSCs (passage 0 – p0). 
JunB expression was confirmed in both control and PE unpassaged PDMSCs, thus excluding the 
presence of cell culturing artefacts. Importantly, Real Time PCR and Western Blot analyses 
confirmed increased JunB gene (6.87 Fold Increase) and protein (1.47 Fold Increase) levels in p0 
PE-PDMSCs compared to p0 controls (Fig. 2S a and b) as we reported for cells at passage 5. 
3.4. JunB/Fra1 and JunB/Fra2 association 
The dimerization of AP-1 family members is a crucial events to form the active transcription 
complex [14]. We first investigated the expression of Fra-1 and Fra-2, the main JunB dimerization 
partners, in control (n = 20) and PE-PDMSCs (n = 24). Immunoblotting analyses revealed no 
differences in both Fra-1 and Fra-2 protein expression levels between physiological and PE-
PDMSCs (p > 0.05) ( Fig. 2a). 
To determine differences in JunB/Fra-1 and JunB/Fra-2 association, we separately 
immunoprecipitated Fra-1 and Fra-2 proteins and immunoblotted for JunB. No differences were 
found JunB/Fra-1 hetero-dimerization between control and PE-PDMSC (p > 0.05) ( Fig. 2b, left 
panel). In contrast, we found a significant increase in JunB/Fra-2 heterodimer formation in PE-
PDMSC relative to controls (p = 0.03, 1.7 Fold Increase) ( Fig. 2b, right panel). 
3.5. Cyclin D1 expression and JunB siRNA in control PDMSCs 
JunB is a key cell cycle regulator able to arrest the G1/S phase transition through transcriptional 
inhibition of Cyclin D1 [15]. Therefore, we investigated whether JunB over-expression in PE-
PDMSCs was accompanied by aberrant Cyclin D1 expression. We found that Cyclin D1 mRNA 
(p = 0.001, 1.53 Fold Decrease) and protein (p = 0.016, 5.55 Fold Decrease) expression levels were 
significantly down-regulated in PE-PDMSCs relative to controls ( Fig. 3a and b). 
In order to determine the functional significance of JunB-mediated Cyclin D1 regulation in our experimental 
model, we silenced JunB gene expression by siRNA technology. We optimized siRNA protocol by initially 
using three different JunB siRNA duplexes (D1, D2 and D3). Real Time PCR showed that JunB gene 
expression was efficiently silenced by D1 (p = 0.03, 3.1 Fold Decrease) and D3 (p = 0.02, 4.16 Fold 
Decrease) siRNA duplexes relative to control SS siRNA treated cells ( Fig. 4a). Decreased JunB levels were 
associated to increased Cyclin D1 mRNA expression in PDMSCs treated by D1 (p = 0.03, 3.23 Fold 
Increase) and D3 (2.63 Fold Increase) siRNA duplexes compared to SS siRNA treated cells ( Fig. 4a and b, 
left panel). Western Blot analyses (Fig. 4a and b, right panel) showed decreased JunB (D1: 1.78 Fold 
Decrease; D3: 1.96 Fold Decrease) and increased Cyclin D1 (D1: 1.2 Fold Increase; D3: 1.12 Fold Increase) 
protein expression levels in JunB siRNA PDMSCs compared to SS siRNA control cells, thus confirming 
data obtained at mRNA level. 
4. Discussion 
In the present study we demonstrated, for the first time, a differential AP-1 expression pattern in 
preeclamptic relative to physiological chorionic mesenchymal stromal cells. In particular, we 
reported JunB over-expression accompanied by increased JunB/Fra2 dimerization and Cyclin D1 
downregulation in PE-PDMSCs. These data suggest augmented JunB pathway activation in PE-
PDMSCs and its possible involvement in the transcriptional regulation of the key cell cycle 
mediator Cyclin D1, which is a proto-oncogene regulator of G1/S phase progression. Therefore, 
PDMSCs defects could contribute to the aberrant villous architecture typical of PE pregnancies with 
fetal-placental compromise. 
It was previously demonstrated that AP-1 transcription factors are critical for normal development 
and neoplastic transformation of different cell types such as hepatocytes, keratinocytes and 
lymphocytes [17], [18], [19], [20] and [21]. Our group recently showed decreased c-Fos and Fra-2 
expression in PE relative to physiological trophoblast cells [10]. These findings are indicative of 
altered placental AP-1 expression pattern that might contribute to the impaired trophoblast 
development typical of preeclampsia. 
Caplan et al. showed that mesenchymal stromal cells, beside possessing well renowned stem cells-
like features like high proliferative and self-renewal potentials [22], are able to control proliferation 
and apoptosis in neighbouring cells through secretion of trophic mediators [23]. We recently 
reported aberrant release of pro-inflammatory cytokines and anti-angiogenic molecules by PDMSCs 
derived from PE placentae, indicating a direct contribution of this specific cell population to the 
anomalies typical of PE [7]. 
Herein, we found that all AP-1 molecules were expressed in placental-derived MSC except for 
FosB, not present in both normal and PE-PDMSCs. Previous studies have shown that FosB−/− mice 
have a physiological birth rate, they are fertile and do not present evident phenotypic or histological 
anomalies [24]. Moreover FosB-deficient embryonic stem cells and mouse embryonic fibroblast 
normally enter the S phase of cell cycle [25]. These data suggest that FosB might not be crucial for 
cell cycle regulation and embryonic development. Otherwise, lack of FosB, usually necessary for 
the osteogenic differentiation of mesenchymal cells [26], may be fundamental for maintaining the 
basal undifferentiated state of MSCs. 
In contrast, we reported JunB over-expression in PE-PDMSCs. AP-1 factors are induced by 
cytokines, oxidative stress and growth factors [27]. Therefore, JunB over-expression in PE-
PDMSCs could be an intrinsic feature and/or result from anomalous cytokine-mediated autocrine 
stimulation. Moreover, JunB over-activation could be further elevated in utero by hypoxia/oxidative 
stress, which is typical of PE placentae [28]. 
AP-1 activity is tightly regulated at the protein level by homo- and hetero-dimerization of Fos and 
Jun proteins. Jun/Fos dimers are required to bind DNA and promote transcription of different target 
genes. In bone marrow dendritic cells, Fra-2 was described as the main JunB dimerization partner 
[29]. However, other studies performed on endothelial cells derived from sheep fetal-placental 
arteries reported Fra-1 as the most suitable factor to dimerize with JunB [30]. Furthermore, lack of 
Fra-1 or JunB in mouse placentation processes could give rise to very similar phenotypes such as a 
non-vascularized placental labyrinth, defects in the yolk sac and embryos severely growth retarded. 
These strikingly similar phenotypes suggest that Fra1 and JunB might have overlapping functions 
during extra-embryonic development, an idea supported by the observations that the temporal and 
spatial expression patterns of Jun-B and Fra1 during embryogenesis are partly overlapping 
[31] and [32]. Herein, we didn't find differences in Fra-1 and Fra-2 protein levels or in the 
formation of Fra-1-JunB heterodimers between PE and control cells. In stark contrast, we 
demonstrated a significant increase in JunB/Fra-2 heterodimer formation in PE-PDMSCs relative to 
control cells. These data suggest that in our model the mechanism leading to the aberration of 
cellular processes typical of PE placentae such as an impaired vascularization is not due to 
JunB/Fra-1 heterodimers, and thus is different to the mouse model. Instead, Fra-2 could be the 
highest affinity partner of JunB in PE and the JunB/Fra-2 heterodimer could be responsible of the 
aberrant cellular processes controlled by JunB such as proliferation and vascular development. 
AP-1 family members regulate expression and function of cell-cycle regulators Cyclin D1, Cyclin 
A, Cyclin E, p53, p21
Cip1
, p16
INK4A
 and p19
ARF
[20] and [33]. In particular, JunB could act as 
inhibitor of cell division [34] and [35], senescence inducer [35] and tumor suppressor [36], 
[37] and [38]. JunB knock-in strategy and transgenic complementation approach demonstrated 
abrogation of proliferation by aberrant regulation of Cyclin D1, p53 and p21
Cip1
 in fibroblast [39]. 
Moreover, a negative correlation between JunB and Cyclin D1 levels, necessary for the rapid 
transition from G1 to S phase of the cell cycle, was observed in primary MEFs [15]. 
The role of JunB and Cyclin D1 in chorionic PDMSCs has never been addressed. Therefore, we 
determined whether JunB over-expression negatively influence Cyclin D1 causing and/or 
contributing to the decreased proliferation rate previously described in PE-PDMSCs [7]. First, we 
demonstrated Cyclin D1 down-regulation in PE-PDMSCs characterized by JunB over-expression. 
Next, we reported that JunB siRNA in physiological PDMSCs leaded to increased Cyclin D1 gene 
expression, confirming JunB-mediated Cyclin D1 regulation in our model. Indeed, aberrant 
JunB/Cyclin D1 balance could affect G1/S cell cycle transition in PE-PDMSCs inducing reduced 
cell proliferation and increased senescence [7]. A recent study demonstrated that fibroblasts derived 
from JunB over-expressing mice display reduced proliferation, due to an extended G1 phase and 
undergo to premature senescence [35]. Furthermore, it was described that JunB absence in the 
myeloid lineage of transgenic mice leaded to increased proliferation of myeloid progenitors [36]. 
Our data are in line with these studies, thus supporting our hypothesis. A significant reductions in 
PDMSCs number could in turn alter their function as a structural support for primary villi formation 
and modify their paracrine activity on trophoblast cells. Importantly the PE-PDMSCs described in 
the present study were all derived from pregnancies with fetal and/or placental compromise. Indeed, 
the JunB/Cyclin-D1 imbalance that we reported in preeclamptic mesenchymal cells may not apply 
to PE pregnancies characterized by normal placentation. 
In conclusion, our data suggest that JunB/Cyclin-D1 inbalance in PE-PDMSCs could contribute to 
the aberrant villous architecture typical of preeclamptic pregnancies with fetal-placental 
compromise. Indeed, PDMSCs could represents a future therapeutic tool or target for human 
placenta-related disorders as preeclampsia. 
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